Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study

[11] Larsen EC(2001)Guide to anticoagulant therapy: heparin : a statement for healthcare professionals from the American Heart Association Circulation 103 2994-1392

[12] Christiansen OB(2008)Heparin and low-molecular-weight heparin Thromb Haemost 99 807-203S

[13] Kolte AM(2020)From unfractionated heparin to pentasaccharide: paradigm of rigorous science growing in the understanding of the in vivo thrombin generation Blood Rev 39 100613-807

[14] Macklon N(2016)Heparin and anticoagulation Front Biosci (Landmark Ed) 21 1372-75

[15] Christiansen OB(2004)Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 188S-456

[16] Nybo Andersen AM(1998)College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban Arch Pathol Lab Med 122 799-839

[17] Bosch E(2019)Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: a systematic literature review of efficacy and cost-effectiveness J Oncol Pharm Pract 25 68-39

[18] Daya S(2014)Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients J Trauma Acute Care Surg 76 450-153

[19] Delves PJ(2012)A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis J Thromb Haemost 10 833-257

[20] Hviid TV(2019)Low molecular weight heparins and their clinical applications Prog Mol Biol Transl Sci 163 21-204

[11] Larsen EC(2001)Guide to anticoagulant therapy: heparin : a statement for healthcare professionals from the American Heart Association Circulation 103 2994-1392

[12] Christiansen OB(2008)Heparin and low-molecular-weight heparin Thromb Haemost 99 807-203S

[13] Kolte AM(2020)From unfractionated heparin to pentasaccharide: paradigm of rigorous science growing in the understanding of the in vivo thrombin generation Blood Rev 39 100613-807

[14] Macklon N(2016)Heparin and anticoagulation Front Biosci (Landmark Ed) 21 1372-75

[15] Christiansen OB(2004)Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 188S-456

[16] Nybo Andersen AM(1998)College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban Arch Pathol Lab Med 122 799-839

[17] Bosch E(2019)Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: a systematic literature review of efficacy and cost-effectiveness J Oncol Pharm Pract 25 68-39

[18] Daya S(2014)Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients J Trauma Acute Care Surg 76 450-153

[19] Delves PJ(2012)A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis J Thromb Haemost 10 833-257

[20] Hviid TV(2019)Low molecular weight heparins and their clinical applications Prog Mol Biol Transl Sci 163 21-204